Showing results for:
Busulfan is FDA approved in combination with cyclophosphamide as a conditioning regimen prior to allogeneic stem cell transplantation for people who have chronic myeloid leukemia.
Busulfex® Myleran® Busulfan
Dexamethasone, hydrocortisone, methylprednisolone and prednisone are FDA approved corticosteroids that are used to treat many medical problems, including some kinds of cancer. Side effects needing medical attention: Swelling of feet and ankles; muscle weakness; ulcers or stomach pain or burning; easy bruising; wounds that are slow to heal; dizziness; severe headaches; menstrual problems; blood-sugar problems; blurred or decreased vision or seeing halos around lights; sore throat and fever; depression; mood or mental changes; indigestion; sleeplessness; nervousness or restlessness; weight gain.
Prednisone Decadron® Medrol® Methylprednisolone Dexamethasone
Gemtuzumab ozogamicin is approved for the treatment ofNewly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older Relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older (1.2).
Mylotarg® Gemtuzumab ozogamicin
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Mustargen® nitrogen mustard Mechlorethamine
Mechlorethamine gel is FDA approved for the treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Valchlor® Mechlorethamine gel
U.S. Food and Drug Administration (FDA) has granted approval of EVOMELA for use in two indications:Use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM)For the palliative treatment of patients with MM for whom oral therapy is not appropriate.This is the first product to be FDA-approved for the high-dose conditioning indication in MM.
Evomela™ Melphalan hydrochloride
Mercaptopurine is FDA approved to treat people who have acute lymphoblastic leukemia as part of a combination regimen.
Purinethol® 6-MP Purixan® Mercaptopurine
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Rheumatrex® Trexall® Methotrexate
Rydapt is FDA approved for the treatment of adult patients with:Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.Limitations of Use:RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Rydapt® Midostaurin
Mitomycin is FDA approved to treat people who have advanced adenocarcinoma of the stomach or pancreas in combination with other approved chemotherapeutic agents and as palliative treatment when other treatments have failed. This medication is sometimes prescribed for other uses such as bladder and lung cancer. Mitomycin sometimes causes a temporary loss of hair. After treatment has ended, normal hair growth should return.
Mutamycin® Mitomycin
Mitoxantrone is FDA approved in combination with other approved drug(s) indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. Mitoxantrone is a dark blue solution that may cause urine to appear blue-green. It may also cause the whites of the eyes to turn a blue color. These effects are normal and last for only 1 or 2 days after each dose is given. This medicine often causes a temporary loss of hair. After treatment with mitoxantrone has ended, normal hair growth should return.
Novantrone® Mitoxantrone
Mogamulizumab is FDA approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Poteligeo® Mogamulizumab
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Momelotinib Ojjaara
Mosunetuzumab-axgb is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mosunetuzumab-axgb Lunsumio™
Moxetumomab pasudotox-tdfk is FDA approved for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Lumoxiti® Moxetumomab pasudotox-tdfk
Plerixafor injection is FDA approved for use along with a granulocyte colony-stimulating factor (G-CSF) medication in preparation for an autologous stem cell transplant in patients with non-Hodgkin lymphoma or myeloma. Plerixafor injection works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplantation.
Mozobil® Plerixafor
Procarbazine is FDA approved with other anticancer drugs for the treatment of stage III and IV Hodgkin lymphoma. Procarbazine is used as part of the MOPP (mechlorethamine, Oncovin® [vincristine], procarbazine, prednisone) regimen. This medicine may cause a temporary loss of hair in some people. After treatment with procarbazine has ended, normal hair growth should return.
Matulane® Procarbazine
Tafasitamab-cxix is approved in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Monjuvi® Tafasitamab-cxix
Vincristine sulfate liposome injection
Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
Marqibo®
Vincristine sulfate liposome injection